Biotinylated Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) (MALS verified)

As verified in competitive ELISA-based and pseudovirus-based neutralization assay, this chimeric monoclonal can potently neutralize all SARS-CoV-2 Variants of Concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) .

Product Specifications

Background

It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

CAS Number

9007-83-4

Host

HEK293

Origin Species

Mouse

Target

Spike RBD

Conjugation

Biotin-labeled

Tag

Mouse IgG1 & Avi | Mouse Kappa

Stability

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles.

Purity

0.95

Bioactivity

Immobilized SARS-CoV-2 Spike Protein, His Tag, Super stable trimer (Cat. No. SPN-C52H9) at 2 μg/mL (100 μL/well) can bind Biotinylated Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AM122) (Cat. No. S1N-VM226) with a linear range of 0.2-13 ng/mL (Routinely tested)